The AIM-HI Accelerator Fund (AIM-HI), together with our partner organizations, the National Foundation for Cancer Research and the Asian Fund for Cancer Research, successfully concluded the 2022 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship on Saturday, October…
ROCKVILLE, MD – The AIM-HI Accelerator Fund (AIM-HI) today announced the recipient of its inaugural Beacon Award for Women Leaders in Oncology as Anna D. Barker, Ph.D., Chief Strategy Officer at the Lawrence J. Ellison Institute for Transformative Medicine. She…
The AIM-HI Accelerator Fund (AIM-HI) brings together a worldwide community of leaders in oncology to bridge the gap between laboratory discoveries and clinical trials, with the ultimate goal of developing innovative cancer therapies and technologies that can save patients’ lives.…
The AIM-HI Accelerator Fund is honored to be nominated for the 2022 Prix Galien USA Incubators, Accelerators and Equity Award. The newest Prix Galien Award category, “Incubators, Accelerators and Equity,” acknowledges the role played by organizations in guiding the next…
ROCKVILLE, MD – AIM-HI Accelerator Fund, a non-for-profit that focuses on supporting early-stage biotechnology companies to progress innovative discoveries into the clinic, announced today that Mr. Lance Kawaguchi, CEO of Cure Brain Cancer Foundation, has been appointed as a strategic…
ROCKVILLE, MD – AIM-HI Accelerator Fund, a non-for-profit that focuses on supporting early-stage biotechnology companies to progress innovative discoveries into the clinic, announced today the launching of its first Beacon Award for Women Leaders in Oncology. This award will be an…
The AIM-HI Accelerator Fund (AIM-HI) just announced 6 Semi-Finalists for the 2022 AIM-HI Women’s Venture Competition! These innovative oncology start-ups have been selected from an exceptional pool of applications submitted by women scientist-entrepreneurs worldwide. The AIM-HI Women’s Venture Competition, now…
On March 31, 2022, the clinical trial application of ARB202 received ethics approval in Australia. ARB202 is an innovative bispecific antibody drug developed by AIM-HI Portfolio Company Arbele, a biotech company based in the Hong Kong Science and Technology Park.…
We're excited that Dr. Sujuan Ba, AIM-HI CEO & Co-Founder, is featured as one of the "20 Most Inspiring Women Leaders 2022" by THE WOMEN LEADERS Magazine. Read about her illustrious career leading three successful non-profits in the field of cancer…
Recently, Sujuan Ba, Ph.D., CEO & Co-Founder of the AIM-HI Accelerator Fund, was featured in the series Profiles in Success as a Scientist Trailblazing the Transformation. In the interview, Dr. Ba highlights her path from determined teen to research and eventually nonprofit leadership.…
